ipamorelin mastery course
Unit 4 of 11

selectivity without the side effects

why ipamorelin gets GH but not cortisol

one receptor, two doors

The molecular puzzle that defines ipamorelin's identity is simple to state: every GHRP-class drug binds the same receptor (GHS-R1a), but only ipamorelin releases GH without dragging ACTH, cortisol, and prolactin along with it. GHRP-6 and hexarelin hit the same target and produce a hormonal mess. Ipamorelin, at the same target, produces a clean pulse. The leading explanation is biased agonism -- two ligands engaging the same receptor in two different conformations that talk to different downstream pathways.

selectivity scorecard

top-line ranking across the GHS-R1a family. detail view is the grid below.

receptor-selectivity dashboard

side-by-side hormone-response curves for GHRP-6, GHRP-2, hexarelin, and ipamorelin.

receptor-selectivity dashboard

key terms

tap to expand.

Bbiased agonismpharmacology
a phenomenon where two ligands binding the same GPCR stabilize different receptor conformations that preferentially couple to different downstream effectors (Gq vs Gi vs beta-arrestin). same target, different signaling profile. the leading hypothesis for ipamorelin's GH-selectivity-over-cortisol pattern.
AACTHhormone
adrenocorticotropic hormone -- a 39-residue pituitary hormone whose main job is telling the adrenal cortex to make cortisol via the MC2R receptor. GHRP-2 and GHRP-6 raise ACTH at GH-releasing doses; ipamorelin does not.
PPRLhormone
prolactin -- a pituitary hormone from lactotrophs. elevated by GHRP-6 and GHRP-2 at GH-releasing doses, not by ipamorelin. prolactin elevation is the side effect that disqualified earlier GHRPs from chronic GH-deficiency use.
HHPA axisendocrinology
the hypothalamic-pituitary-adrenal axis -- the cortisol-production loop. avoiding HPA activation is the whole point of ipamorelin's selectivity over older GHRPs.
Ccorticotrophcell
the ACTH-producing cell of the anterior pituitary. expresses GHS-R1a at lower density than the somatotroph. how GHRP-6 activates this cell while ipamorelin does not -- with the same receptor on both -- is the central biased-agonism puzzle.
Aarcuate nucleusanatomy
the hypothalamic region where ghrelin's appetite-driving neurons live. activated by GHRP-6 (which is why GHRP-6 is famously orexigenic) but largely spared by ipamorelin -- another arm of the selectivity story.

selectivity -- the simple version

same receptor, different conformations, different downstream signals.

If GHRP-6, hexarelin, and ipamorelin all bind GHS-R1a, why do they produce different hormonal effects? The answer is that "binding the receptor" is not a single thing. A receptor is a flexible protein, and different ligands can pin it into different shapes. Each shape talks to different signaling proteins on the inside of the cell.

In somatotrophs, the shape ipamorelin imposes on GHS-R1a couples efficiently to the GH-release pathway. But in corticotrophs and lactotrophs (the cells that make ACTH and prolactin), the same shape couples weakly. GHRP-6, in contrast, imposes a shape that couples to both. Same receptor on both cell types -- different ligand, different conformation, different downstream signal.

The N-terminal Aib and the position-3 D-2-Nal are the residues thought to lock ipamorelin into the GH-favoring conformation. Swap them for the natural residues of GHRP-6 and you get back the hormonal mess. Swap them in and the cortisol and prolactin signal disappears. The structural-biology question is still open at the level of crystal structures, but the functional pattern has held up across 25 years of follow-on work.

advanced: biased-agonism evidence at GHS-R1a

what is documented

Biased agonism at GHS-R1a is documented for several ligands in heterologous expression systems. Ipamorelin's specific Gq/PLC-favoring profile is the working hypothesis.

what is not documented

That profile has not been formally dissected against beta-arrestin recruitment in published live-cell assays the way some other GPCRs have. Allosteric GHS-R1a modulators with even cleaner selectivity are an active research frontier.

practical implication

The selectivity here is a phenotype observation, robust across species, whose structural basis is not fully resolved.

advanced: the Raun 1998 head-to-head experiment

design

The defining experiment compared ipamorelin, GHRP-6, and GHRP-2 in conscious swine on the same day. GH release was equivalent across all three: robust, dose-dependent, pulsatile.

off-target axes

GHRP-2 elevated both ACTH and cortisol significantly. GHRP-6 elevated cortisol moderately. Ipamorelin produced no significant ACTH, cortisol, FSH, LH, TSH, or prolactin elevation.

dose buffer

Selectivity held even when ipamorelin was pushed 200x past the GH ED50. The selectivity advantage has a wide dose buffer in the pig model.

advanced: selectivity at chronic dosing and supra-pharmacologic exposure

where the claim holds

The Raun 1998 selectivity claim is robust within the tested dose range (up to 200x the GH ED50) and the short-course timeframe of those experiments.

where it has not been tested

Whether selectivity is preserved at even higher doses or with chronic daily dosing in humans has not been formally studied. Theoretical concerns include receptor remodeling under repeated agonist exposure and cross-talk activation of corticotroph signaling at supra-pharmacologic concentrations.

honest framing

The absence of published evidence is not evidence of selectivity at all doses indefinitely.

ipamorelin's selectivity claim is its single most important commercial differentiator. it is also the claim most consistently overstated -- "no side effects" is not the same as "no cortisol or prolactin at the doses Novo tested in pigs."

where this has been studied

selectivity evidence from the originator's papers and follow-on work.

Raun 1998 conscious-swine
the defining selectivity paper. GH release equivalent to GHRP-6/GHRP-2; ACTH, cortisol, prolactin, FSH, LH, TSH all unchanged from baseline even at the highest doses tested. the result that the entire ipamorelin literature rests on.
Gobburu 1999 healthy adults
human Phase I -- 48 healthy male volunteers across a 33-fold dose range. GH pulse dose-proportional; selectivity claim consistent with the pig data: no significant ACTH or cortisol elevation reported in the trial.
Ankersen 1998 SAR
the medicinal-chemistry companion documenting that the D-2-Nal substitution at position 3 (replacing L-Trp) is the single residue most responsible for eliminating prolactin/ACTH release. the structural lever for the selectivity phenotype.
chronic-dosing data
no published study of human selectivity under repeated daily dosing over weeks or months. the FDA 2024 PCAC briefing flags this as an open question. community use envelopes are well outside the studied envelope.
the cleaner profile is real, but it does not translate into "approved." ipamorelin's selectivity is its best argument; the lack of a clinical-endpoint trial is its worst. cleanliness on hormone panels and efficacy on patient outcomes are not the same achievement.